These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 1689220)

  • 21. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
    Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L
    Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
    Mueller EA; Anderer FA
    Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
    Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
    Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
    Shau H; Gray JD; Golub SH
    Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of corticosteroid on lymphokine-activated killer (LAK) activity and the change of membrane antigen phenotype on PBMC after IL2 incubation with reference to the evaluation in vitro].
    Yoshimura A
    Nihon Ika Daigaku Zasshi; 1990 Jun; 57(3):211-21. PubMed ID: 2376610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
    Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
    Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
    Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
    Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two populations of mouse lymphokine-activated killer cells separated by use of soybean agglutinin.
    Takano M; Okada T; Maruyama T; Harada K; Imai Y; Osawa T
    Jpn J Cancer Res; 1989 Dec; 80(12):1228-37. PubMed ID: 2516850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2.
    Hellstrand K; Hermodsson S
    Int Arch Allergy Appl Immunol; 1990; 92(4):379-89. PubMed ID: 2150668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
    Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
    J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
    Ozerol I; Ageitos A; Heimann DG; Talmadge JE
    Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
    Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.
    Ebina N; Gallardo D; Shau H; Golub SH
    Br J Cancer; 1990 Oct; 62(4):619-23. PubMed ID: 1699593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of interleukin 4 upon human tumoricidal cells obtained from patients bearing solid tumors.
    Jadus MR; Good RW; Crumpacker DB; Yannelli JR
    J Leukoc Biol; 1991 Feb; 49(2):139-51. PubMed ID: 1991997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of human lymphokine (IL-2)-activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes.
    Sone S; Inamura N; Nii A; Ogura T
    Int J Cancer; 1988 Sep; 42(3):428-34. PubMed ID: 3262092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
    Sarneva M; Vujanovic NL; Van den Brink MR; Herberman RB; Hiserodt JC
    Cell Immunol; 1989 Feb; 118(2):448-57. PubMed ID: 2910504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of lymphokine-activated killer cell activity by low-dose recombinant interleukin-2 and tumor cells.
    Yamamoto S; Hoon DS; Chandler P; Schmid I; Irie RF
    Cell Immunol; 1990 Jul; 128(2):516-27. PubMed ID: 1972659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.